Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H299
UPID:
SH3L3_HUMAN
Alternative names:
SH3 domain-binding protein 1; TNF inhibitory protein B1
Alternative UPACC:
Q9H299; Q5T122
Background:
SH3 domain-binding glutamic acid-rich-like protein 3, also known as SH3 domain-binding protein 1 or TNF inhibitory protein B1, plays a crucial role in cellular processes. It is a probable modulator of glutaredoxin biological activity and is implicated in cytoskeleton organization, as evidenced by recent research.
Therapeutic significance:
Understanding the role of SH3 domain-binding glutamic acid-rich-like protein 3 could open doors to potential therapeutic strategies.